Jeff Hatfield, Vividion CEO

‘Pluck those di­a­monds’: Bay­er’s Vi­vid­ion eyes up to nine on­col­o­gy tar­gets from Duke spin­out

Af­ter snap­ping up Vi­vid­ion be­fore it could jump on­to Nas­daq last Au­gust, Bay­er’s pre­clin­i­cal ‘arms-length’ sub­sidiary is bet­ting on a rel­a­tive­ly un­known North Car­oli­na up­start in a five-year pact.

The ini­tial fo­cus con­cerns four tar­gets, but the deal with Durham-based Tavros Ther­a­peu­tics could bal­loon by an­oth­er five tar­gets, which would more than dou­ble the terms from $430.5 mil­lion in mile­stones to a whop­ping $912 mil­lion. Ei­ther way, the 14-em­ploy­ee Tavros gets $17.5 mil­lion up­front.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.